# Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

Study · id `cardio:ct-nct04258488` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04258488](<https://clinicaltrials.gov/study/NCT04258488>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04258488

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1300 participants.

## Technical summary

Registry record NCT04258488. Randomized; no masking; primary purpose treatment. Start 2022-02-21 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1300 participants (planned count; ClinicalTrials.gov record NCT04258488, source copy `cardio:ctgov-nct04258488-2026-07-06`, retrieved 2026-10-26)
- Started: 2022-02-21 (actual) (ClinicalTrials.gov record NCT04258488, source copy `cardio:ctgov-nct04258488-2026-07-06`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04258488, source copy `cardio:ctgov-nct04258488-2026-07-06`, retrieved 2026-10-26)
- Completion: 2028-12-30 (anticipated) (ClinicalTrials.gov record NCT04258488, source copy `cardio:ctgov-nct04258488-2026-07-06`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04258488, source copy `cardio:ctgov-nct04258488-2026-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04258488-2026-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
- Acronym: RENOVATE
- Condition: AORTIC VALVE DISEASES
- Condition: Thromboembolism
- Intervention (Drug): Rivaroxaban Oral Tablet
- Intervention (Drug): Vitamin K antagonist(warfarin)
- Lead sponsor: Joon Bum Kim
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 12fcfd7ba847121e5aea0a76ae95af90d516e75ab743588a2f918f604dd01b85
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
